Sun Pharma is expected to report healthy double-digit revenue growth in the March quarter, supported by strong performance in speciality drugs, domestic formulations and emerging markets. Brokerages expect the company's US speciality portfolio, particularly newer products such as Unloxcyt and Leqselvi, to remain key growth drivers during the quarter.
According to Motilal Oswal, Sun Pharma is likely to report around 13% year-on-year (YoY) revenue growth in Q4FY26. The brokerage expects growth to be driven by strong performance in India, emerging markets and rest-of-world markets, along with incremental recovery in the US business.
